About This Video
On the latest CSE Issuer Update, host James Black sits down with Emma Andrews, CEO of Nextleaf Solutions Ltd. (CSE: OILS | OTCQB:
OILFF), to discuss the company’s evolution into a capital-efficient, IP-driven cannabinoid processor—and why 2026 is shaping up to be a pivotal year.
Backed by more than 75 global patents focused on cannabinoid extraction and distillation, Nextleaf has built a differentiated platform centered on quality oversight across sourcing, extraction, manufacturing, and distribution—without taking on cultivation risk. With positive EBITDA, positive cash flow, and no debt, the company continues to prioritize disciplined capital allocation while optimizing margins and shifting toward higher-margin bulk ingredient sales.
International expansion is now underway.
Nextleaf recently completed its first export to Australia under a white-label agreement totaling nearly one million soft gels, leveraging its leadership in non-combustible, wellness-oriented formats. Germany is also emerging as a B2B ingredient opportunity as the company scales its export-ready platform.
With digital transformation initiatives supporting growth and new global partnerships forming, Nextleaf is positioning for meaningful revenue expansion through 2026 and 2027.
“This is a truly transformative year for us—we’ve built the foundation, and now we’re scaling globally.” — Emma Andrews
Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe
STAY CONNECTED WITH THE CSE
=============================
- NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
- PODCAST: https://blog.thecse.com/cse-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
- MAGAZINE: https://issuu.com/thecse/docs
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
Investors that have known us for a little while might be familiar. We have over 75 global patents and this relates to processing of cannabinoids. I know it's a tongue twister. We like to do that and trip people up with the with the many alliterations in cannabis, but yeah, we're a cannabinoid processor and our IP portfolio allows us to do this with economical advantages and efficiency advantages compared to our
peers in the industry.



